Compare ALT & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALT | NEWT |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 395.5M |
| IPO Year | 2005 | N/A |
| Metric | ALT | NEWT |
|---|---|---|
| Price | $3.99 | $12.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $15.50 | $14.00 |
| AVG Volume (30 Days) | ★ 2.8M | 163.5K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.29% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $756,308.50 | $12.45 |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $9.12 |
| 52 Week High | $7.73 | $14.91 |
| Indicator | ALT | NEWT |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 43.43 |
| Support Level | $3.78 | $11.72 |
| Resistance Level | $4.25 | $12.41 |
| Average True Range (ATR) | 0.24 | 0.46 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 41.64 | 49.05 |
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.